Clinical trials: PD1
Melanoma
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma.
- Trial name
- NCT03241927
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nina Bhardwaj
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Parkinson Disease, Parkinsonian Disorders
Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson's disease (PD) is a degenerative disease that can be difficult to diagnose. The clinicopathological studies had demonstrated a 76% accuracy in the clinical diagnosis of PD.
- Trial name
- NCT01380899
- Testing
- Biopsy of skin
- Where
- Mexico
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí